Welcome to our dedicated page for Health Catalyst SEC filings (Ticker: HCAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the story behind Health Catalyst’s adaptive data platform inside a 300-page filing can feel overwhelming. Revenue split between Technology subscriptions and Professional Services, HIPAA risk factors, and contract backlog all sit deep in footnotes—yet they drive valuation. If you have ever asked, “Where can I find the Health Catalyst quarterly earnings report 10-Q filing?” or searched for “Health Catalyst insider trading Form 4 transactions,” this page removes the friction.
Stock Titan’s AI reads every submission the instant it hits EDGAR and surfaces exactly what matters. Our tool converts a dense Health Catalyst annual report 10-K simplified into plain language, flags new 8-K material events explained, and delivers Health Catalyst Form 4 insider transactions real-time so you spot executive stock moves without parsing tables. Need context on incentive plans? The Health Catalyst proxy statement executive compensation section is summarized alongside key metrics. You will also find links to each Health Catalyst earnings report filing analysis, plus guidance for understanding Health Catalyst SEC documents with AI if you are new to regulatory language.
Whether you are monitoring segment margin trends, tracking Health Catalyst executive stock transactions Form 4, or comparing sequential growth across hospitals served, every disclosure type—from 10-Q updates to 8-K contract wins—is here with real-time alerts. Analysts use these insights to model recurring revenue, portfolio managers watch insider buys for conviction signals, and healthcare strategists examine risk factor evolution. Explore the complete library now and see Health Catalyst SEC filings explained simply—so your next decision starts with clarity, not complexity.
Albert Benjamin, President and COO of Health Catalyst, Inc. (HCAT), was granted 467,000 restricted stock units (RSUs) on 09/24/2025 under the companys 2019 Stock Option and Incentive Plan. Each RSU represents a contingent right to one share of common stock. After the grant, the filing reports 577,870 shares beneficially owned by the reporting person. The RSUs vest 33.33% on September 10, 2026, with the remaining 66.67% vesting in eight equal quarterly installments thereafter.
Albert Benjamin filed an initial Form 3 reporting his beneficial ownership in Health Catalyst, Inc. (HCAT). He directly holds 92,870 common shares and 18,000 restricted stock units (RSUs) granted under the 2019 Plan that vest beginning March 1, 2026. He also reports indirect holdings of 148,198 shares via the "Benjamin Albert Declaration of Trust" and 28,697 shares via the "Albert Family Trust." The filing is signed by an attorney-in-fact on 09/26/2025.
Benjamin Landry, General Counsel of Health Catalyst, Inc. (HCAT), reported a sale of 6,175 shares of the issuer's common stock on 09/05/2025 at a reported price of $3.353 per share. After the transaction, the reporting person beneficially owned 141,812 shares, held directly. The filing states the sale was executed pursuant to a written trading plan adopted on March 1, 2025 under Rule 10b5-1, providing pre-established instructions for the disposition. The Form 4 was signed on 09/09/2025.
Whetstone Capital Advisors, LLC and David Atterbury report beneficial ownership of 3,731,350 shares of Health Catalyst, Inc. common stock, representing 5.4% of the class. The filing shows the holders have shared voting and shared dispositive power over all 3,731,350 shares and no sole voting or dispositive power. The statement is submitted on a Schedule 13G related to the June 30, 2025 event and includes the filers' Kansas address and Health Catalyst's principal executive office in South Jordan, Utah. The filing includes a certification that the securities were not acquired to change or influence control of the issuer.
Julie Larson-Green, a director of Health Catalyst, Inc. (HCAT), had 4,588 restricted stock units (RSUs) vest on September 1, 2025. Each RSU converts to one share of common stock and the reported transaction shows no cash paid for the award. Following the vesting, Ms. Larson-Green is reported to beneficially own 115,839 shares directly. The Form 4 was signed on September 5, 2025, by an attorney-in-fact for the reporting person.
Health Catalyst, Inc. (HCAT) director Gallagher Duncan received an award of 4,970 restricted stock units (RSUs) that vested in full on September 1, 2025. Each RSU converts into one share of common stock; the filing reports no cash price for the award and shows Mr. Duncan beneficially owns 118,252 shares following the vesting. The Form 4 was signed by an attorney-in-fact on September 5, 2025 and reflects the director relationship of the reporting person.
Health Catalyst, Inc. (HCAT) reported a Form 144 notice for an intended sale of 6,175 common shares, with an aggregate market value of $20,377.50, scheduled approximately for 09/05/2025. The shares were acquired as restricted stock units (RSUs) on 09/01/2025 and recorded as paid on the same date. The filing shows there are 70,373,625 shares outstanding for the issuer and names Morgan Stanley Smith Barney LLC as the broker for the proposed sale on NASDAQ. The Form 144 also discloses a recent sale by the same person of 3,138 shares on 09/02/2025 for $10,552.15. The filer represents no undisclosed material adverse information.
Ross David Coy, Chief Technology & Product Officer of Health Catalyst, Inc. (HCAT), reported a non-discretionary sale of 3,360 shares of common stock on 09/02/2025 at an average price of $3.3627 per share. The filing states the sale was a sell-to-cover transaction to satisfy tax withholding obligations tied to vesting restricted stock units and was not a discretionary trade. After the transaction the reporting person beneficially owns 204,219 shares, held directly. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/04/2025.
Kevin Lee Freeman, Chief Commercial Officer of Health Catalyst, Inc. (HCAT), reported a non-discretionary sale of 4,578 shares of common stock on 09/02/2025 at a price of $3.3627 per share to satisfy tax-withholding obligations tied to the vesting of restricted stock units. The filing lists 375,087 shares beneficially owned by Freeman after the transaction. The disclosure clarifies this was a sell-to-cover transaction required by the issuer's equity plan and was not a voluntary sale by the reporting person.
FAQ
What is the current stock price of Health Catalyst (HCAT)?
What is the market cap of Health Catalyst (HCAT)?
